ARROTEX Pharmaceuticals and Pfizer Australia have inked a new strategic commercial partnership, under which Arrotex will represent Enbrel (etanercept) across Australian community and hospital pharmacy channels, as well as prescriber channels.
The move is part of Pfizer's recognition of the critical and evolving role of community pharmacy within the Australian healthcare landscape, and reflects its commitment to further engage with and invest in the sector.
Key outcomes for pharmacies include enhanced commercial value through the integration of Enbrel into Arrotex's established partnerships platform and a new opportunity for pharmacy to access value associated with a longstanding originator brand.
Arrotex Chief Commercial Officer Hayley Tamborini commented, "We are proud to enter our first partnership with Pfizer - an important milestone for our organisation and a strong endorsement of our partnerships platform.
"Representing a Pfizer-partnered product within this structure enables us to deliver additional commercial value to pharmacies on a product not previously included in such programs," she explained.
The Arrotex sales team has begun engaging with aligned pharmacies on Enbrel.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Feb 26
